BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 31105570)

  • 1. Current Development of siRNA Bioconjugates: From Research to the Clinic.
    Chernikov IV; Vlassov VV; Chernolovskaya EL
    Front Pharmacol; 2019; 10():444. PubMed ID: 31105570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung.
    Günther M; Lipka J; Malek A; Gutsch D; Kreyling W; Aigner A
    Eur J Pharm Biopharm; 2011 Apr; 77(3):438-49. PubMed ID: 21093588
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges.
    Gomes-da-Silva LC; Fonseca NA; Moura V; Pedroso de Lima MC; Simões S; Moreira JN
    Acc Chem Res; 2012 Jul; 45(7):1163-71. PubMed ID: 22568781
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecularly engineered siRNA conjugates for tumor-targeted RNAi therapy.
    Lee JW; Choi J; Choi Y; Kim K; Yang Y; Kim SH; Yoon HY; Kwon IC
    J Control Release; 2022 Nov; 351():713-726. PubMed ID: 36152808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics.
    Kulkarni JA; Witzigmann D; Chen S; Cullis PR; van der Meel R
    Acc Chem Res; 2019 Sep; 52(9):2435-2444. PubMed ID: 31397996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular delivery in vivo of siRNA-based therapeutics.
    Aigner A
    Curr Pharm Des; 2008; 14(34):3603-19. PubMed ID: 19075737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A low molecular weight fraction of polyethylenimine (PEI) displays increased transfection efficiency of DNA and siRNA in fresh or lyophilized complexes.
    Werth S; Urban-Klein B; Dai L; Höbel S; Grzelinski M; Bakowsky U; Czubayko F; Aigner A
    J Control Release; 2006 May; 112(2):257-70. PubMed ID: 16574264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted CRM197-PEG-PEI/siRNA Complexes for Therapeutic RNAi in Glioblastoma.
    Höbel S; Appeldoorn CC; Gaillard PJ; Aigner A
    Pharmaceuticals (Basel); 2011 Dec; 4(12):1591-1606. PubMed ID: 27721338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs.
    Aigner A
    J Biotechnol; 2006 Jun; 124(1):12-25. PubMed ID: 16413079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemical and structural modifications of RNAi therapeutics.
    Ku SH; Jo SD; Lee YK; Kim K; Kim SH
    Adv Drug Deliv Rev; 2016 Sep; 104():16-28. PubMed ID: 26549145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current Aspects of siRNA Bioconjugate for In Vitro and In Vivo Delivery.
    Tai W
    Molecules; 2019 Jun; 24(12):. PubMed ID: 31200490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonviral pulmonary delivery of siRNA.
    Merkel OM; Kissel T
    Acc Chem Res; 2012 Jul; 45(7):961-70. PubMed ID: 21905687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting.
    De Paula D; Bentley MV; Mahato RI
    RNA; 2007 Apr; 13(4):431-56. PubMed ID: 17329355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in targeted delivery of small interfering RNA using simple bioconjugates.
    Nielsen C; Kjems J; Sørensen KR; Engelholm LH; Behrendt N
    Expert Opin Drug Deliv; 2014 May; 11(5):791-822. PubMed ID: 24669756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strategies for in vivo delivery of siRNAs: recent progress.
    Higuchi Y; Kawakami S; Hashida M
    BioDrugs; 2010 Jun; 24(3):195-205. PubMed ID: 20462284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functionalized non-viral cationic vectors for effective siRNA induced cancer therapy.
    Gupta K; Puri A; Shapiro BA
    DNA RNA Nanotechnol; 2017 May; 4(1):1-20. PubMed ID: 34322587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonviral in vivo delivery of therapeutic small interfering RNAs.
    Aigner A
    Curr Opin Mol Ther; 2007 Aug; 9(4):345-52. PubMed ID: 17694447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent progress in development of siRNA delivery vehicles for cancer therapy.
    Kim HJ; Kim A; Miyata K; Kataoka K
    Adv Drug Deliv Rev; 2016 Sep; 104():61-77. PubMed ID: 27352638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNA interference: the molecular immune system.
    Bagasra O; Prilliman KR
    J Mol Histol; 2004 Aug; 35(6):545-53. PubMed ID: 15614608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural Modifications of siRNA Improve Its Performance In Vivo.
    Chernikov IV; Ponomareva UA; Chernolovskaya EL
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.